Study In People With Type 2 Diabetes

Inclusion criteria

* Subjects with T2DM as defined by the criteria of the ADA and/or recognized by WHO Expert Committee on the Diagnosis and Classification of Diabetes Mellitus \[American Diabetes Association, 2004\], for at least 3 months preceding screening (see Section 15.3, Appendix 3:, Diagnosis and Classification of Diabetes Mellitus). * To be eligible for Randomization into the trial, a subject must satisfy all of the following glycemic criteria: * HbA1c level via central laboratory at the pre-screening visit * If HbA1c ≥ 8.0% but ≤ 10.0%: subject may proceed to Randomization; * If HbA1c ≥ 7.8% but \< 8.0%, subject not eligible to proceed, but may be retested once to establish eligibility (or lack thereof). If HbA1c level ≥ 8.0% upon retest, subject is eligible to proceed; otherwise they should be withdrawn. * If HbA1c \< 7.8%, subject not eligible to proceed (no retest allowed). * FPG level via central laboratory at the pre-screening visit must be \< 270 mg/dL (15.0 mmol/L). FPG may be retested within a week to confirm eligibility (or lack thereof). * Concurrent T2DM therapy: * Diet and/or exercise treated: Must not have taken antidiabetic medication for at least 2 months prior to the pre-screening visit, OR * Metformin monotherapy: Subjects entering the study on metformin must be on the same dose, formulation and regimen of metformin for at least 2 months prior to the pre-screening visit, AND * TZDs and insulin are excluded in the 3 months prior to the Screening visit for all subjects. * Males and females who are 18 to 70 years of age inclusive at the time of Screening. * If female, eligible to enter and participate in this study: * If of non-childbearing potential (i.e., physiologically incapable of becoming pregnant (tubal ligation), including any female who is post-menopausal \[\>1 year without menstrual period\]); or, * If of child-bearing potential, has a negative pregnancy test at Screening (serum), at Randomization (urine) and: * Has a male partner who is sterile prior to the female subject's entry into the study and is the sole sexual partner for that female subject, or * Uses double-barrier methods of contraception; condoms with the use of caps (with spermicide) and IUDs are acceptable, or * Uses hormonal contraceptives (oral, depots, patches etc) with double- barrier methods of contraception as outlined above, or * Abstains from sexual intercourse, or * Is with a same sex partner and does not participate in bisexual activities where there is any risk of pregnancy. * Body Mass Index (BMI): ≥25 and ≤40 kg/m² and weigh at least 50 kg at Screening. * If subject is a smoker, must be able to abstain while in clinic at each visit. * Subject has given full written informed consent prior to any study related procedures are performed.